Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer
2022 · Journal of Clinical Investigation · 50 citations
https://doi.org/10.1172/jci157726
X
Xiufeng Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
55
Papers
368
Citations
11
h-index
12
i10-index
Xiufeng Liu is an academic researcher from Capital Medical University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Melanoma and MAPK Pathways. The author has an h-index of 11, co-authored 47 publications.
ORCID: 0000-0003-3888-0333Papers by this author
worksChinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer
2022 · Journal of the National Cancer Center · 23 citations
https://doi.org/10.1016/j.jncc.2022.08.006
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
2024 · BMC Cancer · 13 citations
https://doi.org/10.1186/s12885-024-12584-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat